Back Hepatitis B

Hepatitis B

EASL 2012: Having Only Wild-type Hepatitis B Virus Predicts Response to Interferon

Chronic hepatitis B patients who do not have 2 common HBV mutations are more likely to achieve undetectable viral load and HBsAg loss when treated with pegylated interferon, according to study findings presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.alt

Read more:

May Is Hepatitis Awareness Month

May is designated as Hepatitis Awareness Month in the U.S., an opportunity to promote better understanding of and encourage testing and care for viral hepatitis.alt

Read more:

EASL 2012: Entecavir plus Tenofovir for Hepatitis B Patients with Prior Treatment Failure

A combination of entecavir (Baraclude) plus tenofovir (Viread) resulted in hepatitis B virus (HBV) suppression in a majority of patients who previously experienced treatment failure, according to a study presented at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012) this week in Barcelona.alt

Read more:

EASL 2012: Brivanib Did Not Improve Overall Liver Cancer Survival, but Did Show Anti-tumor Activity

The experimental cancer drug brivanib did not lengthen overall survival for patients with hepatocellular carcinoma, but it did increase time to progression, demonstrating that it had anti-tumor activity, researchers reported at the 47th International Liver Congress (EASL 2012) last week in Barcelona.alt

Read more:

EASL International Liver Congress Starts This Week in Barcelona

The 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012) takes place this week, April 18-22, in Barcelona. HIVandHepatitis.com will be on site to provide breaking news and analysis.alt

Read more:

Complete Coverage of the 2012 International Liver Congress

HIVandHepatitis.com coverage of the 2012 International Liver Congress -- 47th Annual Meeting of the European Association for the Study of the Liver (EASL), April 18-22.

Conference highlights include experimental hepatitis C therapies, interferon-free regimens, boceprevir (Victrelis) and telaprevir (Incivek/Incivo) in real-world practice, difficult-to-treat patients, HIV/HCV coinfection, hepatitis B research, and liver cancer research.

Full listing by topic

HIVandHepatitis.com EASL 2012 conference section

4/25/12

alt

 

Androgens Promote Hepatitis B Virus Replication, Helping Explain Sex Differences

The hepatitis B virus (HBV) carries receptors for androgens -- male hormones such as testosterone -- which may help explain why men are more likely than women to develop chronic hepatitis B and experience more aggressive liver disease, according to study findings reported in the February 2012 Journal of Virology.alt

Read more:

EASL 2012: Entecavir (Baraclude) Prevents Hepatitis B Recurrence after Liver Transplant

No patients treated with entecavir (Baraclude) after receiving liver transplants due to complications of chronic hepatitis B experienced virological recurrence, according to a study described at the 47th International Liver Congress (EASL 2012) last week in Barcelona.

Read more:

Statins May Reduce Liver Cancer Risk among People with Hepatitis B

Statins, a class of drugs used to manage elevated blood cholesterol, may also play a role in fighting hepatocellular carcinoma (HCC) -- a form of primary liver cancer -- among people with chronic hepatitis B, according to a report in the January 23, 2012, advance online edition of the Journal of Clinical Oncology.

Read more: